1. Home
  2. MNY vs SCYX Comparison

MNY vs SCYX Comparison

Compare MNY & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MoneyHero Limited

MNY

MoneyHero Limited

HOLD

Current Price

$0.92

Market Cap

41.9M

Sector

N/A

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$5.23

Market Cap

37.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNY
SCYX
Founded
2014
1999
Country
Singapore
United States
Employees
240
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.9M
37.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
MNY
SCYX
Price
$0.92
$5.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$4.00
$3.00
AVG Volume (30 Days)
11.2K
231.6K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$19.58
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.78
$0.57
52 Week High
$2.40
$5.62

Technical Indicators

Market Signals
Indicator
MNY
SCYX
Relative Strength Index (RSI) 38.34 65.23
Support Level $0.78 $0.65
Resistance Level $1.03 $5.62
Average True Range (ATR) 0.05 0.45
MACD 0.00 0.11
Stochastic Oscillator 0.00 83.08

Price Performance

Historical Comparison
MNY
SCYX

About MNY MoneyHero Limited

MoneyHero Ltd is a tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia. It operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The company has four operating and reportable segments: Hong Kong, Singapore, the Philippines, and Taiwan. The Hong Kong segment generates the majority of the revenue.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: